Jung‐Won Woo

539 total citations
10 papers, 425 citations indexed

About

Jung‐Won Woo is a scholar working on Molecular Biology, Immunology and Rheumatology. According to data from OpenAlex, Jung‐Won Woo has authored 10 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Rheumatology. Recurrent topics in Jung‐Won Woo's work include Immune Response and Inflammation (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Pharmacological Effects of Natural Compounds (2 papers). Jung‐Won Woo is often cited by papers focused on Immune Response and Inflammation (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Pharmacological Effects of Natural Compounds (2 papers). Jung‐Won Woo collaborates with scholars based in South Korea. Jung‐Won Woo's co-authors include Sung‐Hwan Park, Kwi Young Kang, Mi‐La Cho, Seung‐Ki Kwok, Dong‐Gun Lee, Suhyeon Kim, Charles D. Surh, Tae Jin Kim, Chang‐Woo Lee and Kyung-Taek Lim and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jung‐Won Woo

9 papers receiving 415 citations

Peers

Jung‐Won Woo

IMMUN

EPIDE

ONCOL

RHEUM

Xiaojin Liu China

Nada Marjanović United States

Kyoko Takahashi Japan

Weimin She China

Daiane Boff Brazil

Peter M. Grin Canada

Zhigang Chen United States

Honglin Xu China

Suniti Bhaumik United States

Guozhong Gong China

Xiaojin Liu China

Jung‐Won Woo

158 ×0.7

IMMUN

199 ×1.2

105 ×0.9

EPIDE

67 ×1.0

ONCOL

45 ×1.0

RHEUM

Citations per year, relative to Jung‐Won Woo Jung‐Won Woo (= 1×) peers Xiaojin Liu

Countries citing papers authored by Jung‐Won Woo

Since Specialization

Citations

This map shows the geographic impact of Jung‐Won Woo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jung‐Won Woo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jung‐Won Woo more than expected).

Fields of papers citing papers by Jung‐Won Woo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jung‐Won Woo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jung‐Won Woo. The network helps show where Jung‐Won Woo may publish in the future.

Co-authorship network of co-authors of Jung‐Won Woo

This figure shows the co-authorship network connecting the top 25 collaborators of Jung‐Won Woo. A scholar is included among the top collaborators of Jung‐Won Woo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jung‐Won Woo. Jung‐Won Woo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Cho, Byoung Chul, Ki Hyeong Lee, Ji‐Youn Han, et al.. (2024). 605 Vactosertib, a TGF-β signaling inhibitor, in combination with durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC. Regular and Young Investigator Award Abstracts. A696–A696.

Sohn, Joohyuk, Kyong Hwa Park, Hee Kyung Ahn, et al.. (2020). Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).. Journal of Clinical Oncology. 38(15_suppl). 1072–1072. 3 indexed citations

Woo, Jung‐Won, et al.. (2019). 114-LB: GX-G6, a Novel Long-Acting Glucagon-Like Peptide Receptor Agonist: Result of Phase I Study in Healthy Volunteers. Diabetes. 68(Supplement_1). 1 indexed citations

Peterkova, Valentina, et al.. (2018). 12-Month Effects of Once-Weekly and Twice-Monthly Administration of Hybrid Fc-Fused Human Growth Hormone, GX-H9, Treatment in Pediatric with GHD Deficiency. 89. 1 indexed citations

Min, Hong Ki, Sung‐Min Kim, Jung‐Won Woo, et al.. (2015). Anthocyanin Extracted from Black Soybean Seed Coats Prevents Autoimmune Arthritis by Suppressing the Development of Th17 Cells and Synthesis of Proinflammatory Cytokines by Such Cells, via Inhibition of NF-κB. PLoS ONE. 10(11). e0138201–e0138201. 52 indexed citations

Kim, Tae Jin, Hyun‐Tak Jin, Soo Young Hur, et al.. (2014). Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nature Communications. 5(1). 5317–5317. 197 indexed citations

Jhun, JooYeon, Jennifer Lee, Jae Kyeong Byun, et al.. (2014). Red Ginseng Extract Ameliorates Autoimmune Arthritis via Regulation of STAT3 Pathway, Th17/Treg Balance, and Osteoclastogenesis in Mice and Human. Mediators of Inflammation. 2014. 1–13. 32 indexed citations

Kang, Kwi Young, Jung‐Won Woo, & Sung‐Hwan Park. (2014). S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. The Korean Journal of Internal Medicine. 29(1). 12–12. 63 indexed citations

Lee, Dong‐Gun, Jung‐Won Woo, Seung‐Ki Kwok, Mi‐La Cho, & Sung‐Hwan Park. (2013). MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Experimental & Molecular Medicine. 45(4). e20–e20. 48 indexed citations

10.

Park, Mi‐Kyung, Jin‐Sil Park, Eun‐Mi Park, et al.. (2013). Halofuginone Ameliorates Autoimmune Arthritis in Mice by Regulating the Balance Between Th17 and Treg Cells and Inhibiting Osteoclastogenesis. Arthritis & Rheumatology. 66(5). 1195–1207. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact